Main Article Content
Objective: The objective of this work is to investigate the histological and biochemical consequences of administering Dexmedetomidine (DEX), an alpha-2 adrenergic receptor agonist with notable sedative qualities as well as antioxidant and anti-inflammatory characteristics, in the context of Carbon tetrachloride (CCl4)-induced kidney injury.
Materials and Methods: The experimental design involved the random allocation of 30 Sprague-Dawley rats into three distinct groups. The experimental group designated as Group 1 received a single intraperitoneal administration of 1ml of saline solution containing 0.09% NaCl. Group 2 received an intraperitoneal injection of carbon tetrachloride (CCl4) at a dosage of 2 milliliters per kilogram. Group 3, referred to as the CCl4+Dexmedetomidine group, received a solitary intraperitoneal (i.p.) dosage of 100 µg/kg dexmedetomidine one hour before the intraperitoneal administration of 2mL/kg CCl4.
Results: Extensive necrosis and debris accumulation were observed in the tubules, particularly in the proximal tubules, within the CCl4-applied group. An elevation in malondialdehyde (MDA) concentrations and terminal deoxynucleotidyl transferase dUTP nick end labelling (TUNEL) positivity, along with a reduction in glutathione (GSH) levels, was found in the renal tissues of the CCl4 experimental group as compared to the control group. In contrast, the CCl4+DEX group exhibited a reduction in the quantity of necrotic tubular cells, levels of MDA, and TUNEL positive. Additionally, there was an elevation in GSH levels compared to the group treated with CCl4 alone.
Conclusions: The administration of dexmedetomidine has been observed to potentially provide a protective effect against renal damage induced by CCl4. This phenomenon could potentially be linked to the modulation of tissue oxidative stress markers and the attenuation of apoptotic rate. The findings of our investigation provide evidence in favour of the utilization of dexmedetomidine as a promising therapeutic drug for mitigating renal injury.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Sehitoglu I, Tumkaya L, Bedir R, Ozer E, Cure MC, Kalkan Y, et al. Protective Effect of Infliximab Against Carbon Tetrachloride – Induced Hepatotoxicity. 2015;34(2):175–82. DOI: https://doi.org/10.1615/JEnvironPatholToxicolOncol.2015013126
Kauppinen T, Pukkala E, Saalo A, Sasco AJ. Exposure to chemical carcinogens and risk of cancer among Finnish laboratory workers. Am J Ind Med. 2003;44(4):343–50. DOI: https://doi.org/10.1002/ajim.10278
Nagano K, Sasaki T, Umeda Y, Nishizawa T, Ikawa N, Ohbayashi H, et al. Inhalation carcinogenicity and chronic toxicity of carbon tetrachloride in rats and mice. Inhal Toxicol. 2007;19(13):1089–103. DOI: https://doi.org/10.1080/08958370701628770
Starkel P, Leclercq IA. Animal models for the study of hepatic fibrosis. Best Pract Res Clin Gastroenterol. 2011;25(2):319–33. DOI: https://doi.org/10.1016/j.bpg.2011.02.004
Kurt A, Tumkaya L, Yuce S, Turut H, Cumhur Cure M, Sehitoglu I, et al. The protective effect of infliximab against carbon tetrachloride-induced acute lung injury. Iran J Basic Med Sci. 2016;19(6):685–91.
Pergel A, Tümkaya L, Çolakoğlu MK, Demiral G, Kalcan S, Özdemir A, et al. Effects of infliximab against carbon tetrachloride-induced intestinal injury via lipid peroxidation and apoptosis. Hum Exp Toxicol. 2019;38(11):1275–82. DOI: https://doi.org/10.1177/0960327119867758
Unsal V, Cicek M, Sabancilar İ. Toxicity of carbon tetrachloride, free radicals and role of antioxidants. Rev Environ Health. 2021;36(2):279–95. DOI: https://doi.org/10.1515/reveh-2020-0048
Khan RA, Khan MR, Sahreen S, Bokhari J. Prevention of CCl4-induced nephrotoxicity with Sonchus asper in rat. Food Chem Toxicol. 2010;48(8–9):2469–76. DOI: https://doi.org/10.1016/j.fct.2010.06.016
Makni M, Chtourou Y, Garoui EM, Boudawara T, Fetoui H. Carbon tetrachloride-induced nephrotoxicity and DNA damage in rats: Protective role of vanillin. Hum Exp Toxicol. 2012;31(8):844–52. DOI: https://doi.org/10.1177/0960327111429140
Khan MR, Rizvi W, Khan GN, Khan RA, Shaheen S. Carbon tetrachloride-induced nephrotoxicity in rats: Protective role of Digera muricata. J Ethnopharmacol. 2009;122(1):91–9. DOI: https://doi.org/10.1016/j.jep.2008.12.006
Striker GE, Smuckler EA, Kohnen PW, Nagle RB. Structural and functional changes in rat kidney during CCl4 intoxication. Am J Pathol. 1968;53(5):769–89.
Khalil I, Ghani M, Khan MR, Akbar F. Evaluation of biological activities and in vivo amelioration of CCl4 induced toxicity in lung and kidney with Abutilon pannosum (G.Forst.) Schltdl. in rat. J Ethnopharmacol. 2020;249(November 2019):112395. DOI: https://doi.org/10.1016/j.jep.2019.112395
Gerlach AT, Dasta JF. Dexmedetomidine: An updated review. Ann Pharmacother. 2007;41(2):245–54. DOI: https://doi.org/10.1345/aph.1H314
Nguyen V, Tiemann D, Park E, Salehi A. Alpha-2 Agonists. Anesthesiol Clin [Internet]. 2017;35(2):233–45. Available from: http://dx.doi.org/10.1016/j.anclin.2017.01.009 DOI: https://doi.org/10.1016/j.anclin.2017.01.009
Dardalas I, Stamoula E, Rigopoulos P, Malliou F, Tsaousi G, Aidoni Z, et al. Dexmedetomidine effects in different experimental sepsis in vivo models. Eur J Pharmacol [Internet]. 2019;856(May):172401. Available from: https://doi.org/10.1016/j.ejphar.2019.05.030 DOI: https://doi.org/10.1016/j.ejphar.2019.05.030
Xiang H, Hu B, Li Z, Li J. Dexmedetomidine Controls Systemic Cytokine Levels through the Cholinergic Anti-inflammatory Pathway. Inflammation. 2014;37(5):1763–70. DOI: https://doi.org/10.1007/s10753-014-9906-1
Sedlak J, Lindsay RH. Estimation of total, protein-bound, and nonprotein sulfhydryl groups in tissue with Ellman’s reagent. Anal Biochem. 1968;25(C):192–205. DOI: https://doi.org/10.1016/0003-2697(68)90092-4
Ohkawa H, Ohishi N, Yagi K. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal Biochem. 1979;95(2):351–8. DOI: https://doi.org/10.1016/0003-2697(79)90738-3
Sung MJ, Kim DH, Jung YJ, Kang KP, Lee AS, Lee S, et al. Genistein protects the kidney from cisplatin-induced injury. Kidney Int [Internet]. 2008;74(12):1538–47. Available from: http://dx.doi.org/10.1038/ki.2008.409 DOI: https://doi.org/10.1038/ki.2008.409
Mercantepe F, Mercantepe T, Topcu A, Yılmaz A, Tumkaya L. Protective effects of amifostine, curcumin, and melatonin against cisplatin-induced acute kidney injury. Naunyn Schmiedebergs Arch Pharmacol. 2018; DOI: https://doi.org/10.1007/s00210-018-1514-4
Clawson GA. Mechanisms of carbon tetrachloride hepatotoxicity. Pathol Immunopathol Res. 1989;8(2):104–12. DOI: https://doi.org/10.1159/000157141
Boll M, Weber LWD, Becker E, Stampfl A. Mechanism of carbon tetrachloride-induced hepatotoxicity. Hepatocellular damage by reactive carbon tetrachloride metabolites. Zeitschrift fur Naturforsch - Sect C J Biosci. 2001;56(7–8):649–59. DOI: https://doi.org/10.1515/znc-2001-7-826
Adewole S, Salako A, Doherty O, Naicker T. Effect of melatonin on carbon tetrachloride-induced kidney injury in Wistar rats. African J Biomed Res. 2010;10(2):153–64. DOI: https://doi.org/10.4314/ajbr.v10i2.50619
Lamia SS, Emran T, Rikta JK, Chowdhury NI, Sarker M, Jain P, et al. Coenzyme Q10 and silymarin reduce ccl4-induced oxidative stress and liver and kidney injury in ovariectomized rats-implications for protective therapy in chronic liver and kidney diseases. Pathophysiology. 2021;28(1):50–63. DOI: https://doi.org/10.3390/pathophysiology28010005
Habashy NH, Kodous AS, Abu-Serie MM. Targeting ROS/NF-κB signaling pathway by the seedless black Vitis vinifera polyphenols in CCl4-intoxicated kidney, lung, brain, and spleen in rats. Sci Rep. 2021;11(1):1–17. DOI: https://doi.org/10.1038/s41598-021-96008-0
Hismiogullari AA, Hismiogullari SE, Karaca O, Sunay FB, Paksoy S, Can M, et al. The protective effect of curcumin administration on carbon tetrachloride (CCl4)-induced nephrotoxicity in rats. Pharmacol Reports. 2015;67(3):410–6. DOI: https://doi.org/10.1016/j.pharep.2014.10.021
Khan MR, Siddique F. Antioxidant effects of Citharexylum spinosum in CCl 4 induced nephrotoxicity in rat. Exp Toxicol Pathol. 2012;64(4):349–55. DOI: https://doi.org/10.1016/j.etp.2010.09.009
Cakir M, Polat A, Tekin S, Vardi N, Taslidere E, Rumeysa Duran Z, et al. The effect of dexmedetomidine against oxidative and tubular damage induced by renal ischemia-reperfusion in rats. Ren Fail. 2015;37(4):704–8. DOI: https://doi.org/10.3109/0886022X.2015.1011550
Chen Y, Feng X, Hu X, Sha J, Li B, Zhang H, et al. Dexmedetomidine ameliorates acute stress-induced kidney injury by attenuating oxidative stress and apoptosis through inhibition of the ROS/JNK signaling pathway. Oxid Med Cell Longev. 2018;2018. DOI: https://doi.org/10.1155/2018/4035310
Feng X, Guan W, Zhao Y, Wang C, Song M, Yao Y, et al. Dexmedetomidine ameliorates lipopolysaccharide-induced acute kidney injury in rats by inhibiting inflammation and oxidative stress via the GSK-3β/Nrf2 signaling pathway. J Cell Physiol. 2019;234(10):18994–9009. DOI: https://doi.org/10.1002/jcp.28539
Chen Y, Luan L, Wang C, Song M, Zhao Y, Yao Y, et al. Dexmedetomidine protects against lipopolysaccharide-induced early acute kidney injury by inhibiting the iNOS/NO signaling pathway in rats. Nitric Oxide - Biol Chem. 2019;85(November 2018):1–9. DOI: https://doi.org/10.1016/j.niox.2019.01.009